


We claim:

DEAV2003/0019

Dr. WI

1. A compound of the formula I



5

I

wherein:

- Ring A is (C3-C8)-cycloalkanediyl or (C3-C8)-cycloalkenediyl, wherein one or more carbon atoms of said (C3-C8)-cycloalkanediyl and (C3-C8)-cycloalkenediyl groups are optionally replaced by oxygen atoms;
- R1, R2 are each independently H, F, Cl, Br, CF₃, OCF₃, (C1-C6)-alkyl, O-(C1-C6)-alkyl, SCF₃, SF₅, OCF₂-CHF₂, (C6-C10)-aryl, (C6-C10)-aryloxy, OH or NO₂; or
- R1 and R2, taken together with the atoms of the phenyl, pyridine, 1-H-pyrrole, thiophene or furan rings to which they are attached, form a fused, partially saturated or unsaturated, bicyclic (C6-C10)-aryl or (C5-C11)-heteroaryl group;
- R3 is H, (C1-C6)-alkyl, (C3-C8)-cycloalkyl, (C1-C3)-alkyl-(C3-C8)-cycloalkyl, phenyl, (C1-C3)-alkyl-phenyl, (C5-C6)-heteroaryl, (C1-C3)-alkyl-(C5-C6)-heteroaryl or (C1-C3)-alkyl which is fully or partially substituted by F;
- W is CH or N, if o = 1;
- W is O, S or NR₉, if o = 0;

- X is (C1-C6)-alkanediyl, wherein one or more carbon atoms of said (C1-C6)-alkanediyl group are optionally replaced by oxygen atoms;
- Y1 is O;
- Y2 is CR¹²R¹³, SO or SO₂;
- n is 0, 1 or 2;
- R4 is H, F or (C1-C6)-alkyl;
- R5 is H, F or (C1-C6)-alkyl;
- R6 is H or (C1-C6)-alkyl; or is F if n is not 0;
- R7 is H, (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, O-(C1-C6)-alkyl, O-(C2-C6)-alkenyl, O-(C2-C6)-alkynyl, (C3-C8)-cycloalkyl, phenyl, (C5-C11)-heteroaryl, O-(C3-C8)-cycloalkyl or O-phenyl,
 wherein said (C1-C6)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, O-(C1-C6)-alkyl, O-(C2-C6)-alkenyl, O-(C2-C6)-alkynyl, O-(C3-C8)-cycloalkyl and O-phenyl groups are optionally substituted by OH, NR¹⁰R¹¹, O-(C1-C6)-alkyl, O-(C2-C6)-alkenyl, O-(C2-C6)-alkynyl, O-(C3-C8)-cycloalkyl, O-phenyl or O-(C5-C11)-heteroaryl, and
 said (C3-C8)-cycloalkyl, phenyl and (C5-C11)-heteroaryl groups are optionally substituted by OH, NR¹⁰R¹¹, O-(C1-C6)-alkyl, O-(C2-C6)-alkenyl, O-(C2-C6)-alkynyl, O-(C3-C8)-cycloalkyl, O-phenyl, O-(C5-C11)-heteroaryl or (C1-C6)-alkyl,
 wherein said (C1-C6)-alkyl substituent is optionally substituted by F (fully or partially) or O-(C1-C6)-alkyl,
 wherein said O-(C1-C6)-alkyl substituent is optionally substituted by F (fully or partially), Cl, Br, I, OH, NR¹⁰R¹¹, CO-(C1-C6)-alkyl, CO-(C6-

C10)-aryl, CO-(C1-C6)-alkyl-(C6-C10)-aryl, CO-(C5-C11)-heteroaryl, C(O)-O-(C1-C6)-alkyl, C(O)-O-(C1-C6)-alkyl-(C6-C10)-aryl, C(O)-O-(C6-C10)-aryl, C(O)-O-(C5-C11)-heteroaryl, SO₂-(C1-C6)-alkyl, SO₂-(C1-C6)-alkyl-(C6-C10)-aryl, SO₂-(C1-C6)-alkyl-SO₂-(C1-C6)-alkyl, SO₂-(C6-C10)-aryl, SO₂-(C5-C11)-heteroaryl; or

R6 and R7, together with the carbon atom to which they are attached, form a (C3-C8)-cycloalkyl group;

R8 is H or (C1-C6)-alkyl;

R9 is H or (C1-C6)-alkyl which is optionally substituted by phenyl;

R10 is H or (C1-C6)-alkyl which is optionally substituted by phenyl;

R11 is H or (C1-C6)-alkyl which is optionally substituted by phenyl;

R12 is H or (C1-C6)-alkyl;

R13 is H or (C1-C6)-alkyl;

and pharmaceutically acceptable salts thereof.

2. The compound of Claim 1 wherein:

Ring A is (C₃-C₈)-cycloalkanediyl or (C₃-C₈)-cycloalkenediyl, wherein one or more of the carbon atoms in said (C₃-C₈)-cycloalkanediyl or (C₃-C₈)-cycloalkenediyl groups are optionally replaced by oxygen atoms;

X is (C1-C6)-alkanediyl, wherein the C1 or C2 carbon atom (with respect to Ring A) in said (C1-C6)-alkanediyl group is optionally replaced by an oxygen atom;

5 and pharmaceutically acceptable salts thereof.

3. The compound of Claim 2 wherein:

Ring A is cis-cyclohexane-1,3-diyl;

10

R1, R2 are each independently H, F, CF₃, (C1-C6)-alkyl, O-(C1-C6)-alkyl or phenyl, or

15

R1 and R2, taken together with the atoms of the phenyl ring to which they are attached, form naphthyl;

R3 is (C1-C6)-alkyl;

W is CH, if o = 1;

20

X is (CH₂)O or CH₂-O-CH₂;

Y1 is O;

25

Y2 is CH₂;

n is 0 or 1;

R4 is H;

30

R5 is H;

R6 is H;

R7 is H, (C1-C6)-alkyl, O-(C1-C6)-alkyl, (C1-C6)-alkyl-O-(C1-C6)-alkyl, (C2-C6)-alkenyl, O-(C2-C6)-alkenyl, O-(C2-C6)-alkynyl or CH₂NR₁₀R₁₁,

5 wherein said (C1-C6)-alkyl, O-(C1-C6)-alkyl, (C2-C6)-alkenyl and O-(C2-C6)-alkenyl groups are optionally substituted by phenyl or (C5-C6)-heteroaryl,

10 wherein said phenyl and (C5-C6)-heteroaryl groups are optionally substituted by (C1-C6)-alkyl, O-(C1-C6)-alkyl or CF₃; or

R6 and R7, taken together with the carbon atom to which they are attached, form (C3-C6)-cycloalkyl;

15 R8 is H;

R10 is (C1-C6)-alkyl;

20 R11 is (C1-C6)-alkyl substituted by phenyl;

and pharmaceutically acceptable salt thereof.

25 4. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of Claim 1.

5. The pharmaceutical composition of Claim 4 further comprising at least one additional active ingredient.

30 6. The pharmaceutical composition of Claim 5 wherein said additional active ingredient has favorable effects on metabolic disturbances or disorders.

7. The pharmaceutical composition of Claim 5 wherein said additional active ingredient is an antidiabetic.

8. The pharmaceutical composition of Claim 5 wherein said additional active ingredient is a lipid modulator.
- 5 9. A method of treating disorders of fatty acid metabolism and glucose utilization comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.
- 10 10. A method of treating disorders of insulin resistance comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.
- 15 11. A method of treating diabetes mellitus including the prevention of the sequelae associated therewith comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.
- 20 12. A method of treating dyslipidemia and sequelae associated therewith comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.
- 25 14. A method of treating disorders of fatty acid metabolism and glucose utilization comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1 in combination with at least one further active compound.
- 30 15. A method of treating disorders of insulin resistance comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1 in combination with at least one further active compound.